Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis on the use of anti-tumor necrosis factor drugs in inflammatory bowel disease;Recomendaciones del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa sobre el uso de fármacos antifactor de necrosis tumoral α en la enfermedad inflamatoria intestinal (2013)

Gastroenterologia y Hepatologia

Volumn 36, Issue 3, 2013, Pages 127-146

  Cabriada, José Luis ^a   Vera, Isabel ^b   Domènech, Eugeni ^c   Barreiro de Acosta, Manuel ^d   Esteve, María ^e   Gisbert, Javier P ^f   Panés, Julia ^c   Gomollón, Fernando ^g  

^a HOSPITAL DE GALDAKAO   (Spain)

^b HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d University Hospital of Santiago de Compostela   (Spain)

^e HOSPITAL MÚTUA DE TERRASSA   (Spain)

^f Instituto de Investigación Sanitaria del Hospital Universitario de La Princesa   (Spain)

^g HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR NECROSIS FACTOR INHIBITOR;

ARTICLE; CROHN DISEASE; HUMAN; SPAIN; ULCERATIVE COLITIS;

COLITIS, ULCERATIVE; COMBINED MODALITY THERAPY; CROHN DISEASE; HUMANS; INFLAMMATORY BOWEL DISEASES; PATIENT SAFETY; SPAIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84875276991     PISSN: 02105705     EISSN: 15789519     Source Type: Journal    
DOI: 10.1016/j.gastrohep.2013.01.002     Document Type: Article

References (215)

1. Domènech E., Esteve-Comas M., Gomollón F., Hinojosa J., Obrador A., Panes J., et al. Recomendaciones para el uso de infliximab (Remicade®) en la enfermedad de Crohn. GETECCU 2001. Gastroenterol Hepatol 2002, 25:162-169.
2. Domènech E., Esteve M., Gomollón F., Hinojosa J., Panés J., Obrador A., et al. Recomendaciones GETECCU-2005 para el uso de infliximab (Remicade®) en la enfermedad inflamatoria intestinal. Gastroenterol Hepatol 2005, 28:126-134.
3. Obrador A., López San Román A., Muñoz P., Fortún J., Gassull M.A. Grupo Español de Trabajo de Enfermedad de Crohn y Colitis Ulcerosa (GETECCU).Guía de consenso sobre tuberculosis y tratamiento de la enfermedad inflamatoria intestinal con infliximab. Gastroenterol Hepatol 2003, 26:29-33.
4. López-San Román A., Obrador A., Fortún J., Muñoz P., Gassull M.A. Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU). Recomendaciones sobre tuberculosis y tratamiento de la enfermedad inflamatoria intestinal con infliximab. Actualización 2006. Gastroenterol Hepatol 2006, 29:81-84.
5. Cabriada J.L., García Sánchez V., Gomollón F., Hinojosa J., López San Román A., Mendoza J.L., et al. Recomendaciones de actuación en pacientes con enfermedad de Crohn que empiezan tratamiento con adalimumab:una guía rápida. Gastroenterol Hepatol 2008, 31:693-697.
6. Rutgeerts P., van Assche G., Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 2004, 126:1593-1610.
7. Targan S., Feagan B., Fedorak R., Lashner B., Panaccione R., Present D., et al. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE trial. Gastroenterology 2007, 132:1672-1683.
8. Sandborn W., Gasink G., Gao L.-L., Blank M., Johanns J., Guzzo C., et al. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med 2012, 367:1519-1528.
9. Dignass A., van Assche G., Lindsay J.O., Lémann M., Söderholm J., Colombel J.F., et al. The second European evidence based consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis 2010, 4:28-62.
10. van Assche G., Dignass A., Reinisch W., van der Woude C.J., Sturm A., de Vos M., et al. The second European evidence based Consensus on the diagnosis and management of Crohn's disease: special situations. J Crohns Colitis 2010, 4:63-101.
11. Dignass A., Eliakim R., Magro F., Maaser C., Chouders Y., Geboes K., et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis. Part 1: definitions and diagnosis. J Crohns Colitis 2012, 6:965-990.
12. Dignass A., Lindsay J.O., Sturm A., Windsord A., Colombel J.F., Allez M., et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis. Part 2: current management. J Crohns Colitis 2012, 6:991-1030.
13. d'Haens G., Panaccione R., Higgins P., Vermeire S., Gassull M., Chowers Y., et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose and how to predict response?. Am J Gastroenterol 2011, 106:199-212.
14. Orlando A., Armuzzi A., Papi C., Annese V., Ardizzone S., Biancone L., et al. The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines: The use of tumor necrosis factor-alpha antagonist therapy in inflammatory bowel disease. Dig Liv Dis 2011, 43:1-20.
15. Targan S.R., Hanauer S.B., van Deventer S.J., Mayer L., Present D.H., Braakman T., et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997, 337:1029-1035.
16. Hanauer S.B., Sandborn W.J., Rutgeerts P., Fedorak R.N., Lukas M., MacIntosh D., et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006, 130:323-333.
17. Hanauer S.B., Feagan B.G., Lichtenstein G., Mayer L.F., Schreiber S., Colombel J.F., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002, 359:1541-1549.
18. Colombel J.F., Sandborn W.J., Rutgeerts P., Enns R., Hanauer S.B., Panaccione R., et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007, 132:52-65.
19. Peyrin-Biroulet L., Deltenre P., de Suray N., Branche J., Sandborn W.J., Colombel J.F. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo controlled trials. Clin Gastroenterol Hepatol 2008, 6:644-653.
20. Behm B.W., Bickston S.J. Tumor necrosis factor alpha antibody for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2008, 1:CD006893.
21. Chaparro M., Panés J., García V., Mañosa M., Esteve M., Merino O., et al. Long-term durability of infliximab treatment in Crohn's disease and efficacy of dose «escalation» in patients losing response. J Clin Gastroenterol 2011, 45:113-118.
22. Fortea-Ormaechea J.I., González-Lama Y., Casis B., Chaparro M., López Serrano P., van Domselaar M., et al. Adalimumab is effective in long-term real life clinical practice in both luminal and perianal Crohn's disease. The Madrid experience Gastroenterol Hepatol 2011, 34:443-448.
23. González-Lama Y., López-San Román A., Marín I., Casis B., Vera I., Bermejo F., et al. Open-label infliximab therapy in Crohn's disease: a long-term multicenter study of efficacy, safety and predictors of response. Gastroenterol Hepatol 2008, 31:421-426.
24. Panaccione R., Colombel J.F., Sandborn W.J., Rutgeerts P., d'Haens G., Robinson A.M., et al. Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn's disease. Aliment Pharmacol Ther 2010, 31:1296-1309.
25. Schnitzler F., Fidder H., Ferrante M., Noman M., Arijs I., van Assche G., et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut 2009, 58:492-500.
26. Sandborn W.J., Rutgeerts P., Enns R., Hanauer S.B., Colombel J.F., Panaccione R., et al. Adalimumab induction therapy for Crohn's disease previously treated with infliximab: a randomized trial (GAIN). Ann Intern Med 2007, 146:829-838.
27. Panaccione R., Sandborn W.J., d' Haens G., Enns R., Wolf D.C., Lomax K.G., et al. Adalimumab maintains long-term remission in moderately to severely active Crohn's disease after IFX failure: 1-year follow-up of GAIN trial. Gastroenterology 2008, 134(Suppl 2):S133-S134.
28. d'Haens G., Baert F., van Assche G., Caenepeel P., Vergauwe P., Tuynman H., et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008, 371:660-667.
29. Baert F., Moortgat L., van Assche G., Caenepeel P., Vergauwe P., de Vos M., et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology 2010, 138:463-468.
30. Schreiber S., Reinisch W., Colombel J.F. Early Crohn's disease shows high levels of remission to therapy with adalimumab: sub-analysis of CHARM. Gastroenterology 2007, 132:A985.
31. Lionetti P., Bronzini F., Salvestrini C., Bascietto C., Canani R.B., dé Angelis G.L., et al. Response to infliximab is related to disease duration in paediatric Crohn's disease. Aliment Pharmacol Ther 2003, 18:425-431.
32. Kugathasan S., Werlin S.L., Martinez A., Rivera M.T., Heikenen J.B., Binion D.G. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease. Am J Gastroenterol 2000, 95:3189-3194.
33. Beaugerie L., Seksik P., Nion-Larmurier I., Gendre J.P., Cosnes J. Predictors of Crohn's disease. Gastroenterology 2006, 130:650-656.
34. Loly C., Belaiche J., Louis E. Predictors of severe Crohn's disease. Scand J Gastroenterol 2008, 43:948-954.
35. Seksik P., Loftus E.V., Beaugerie L., Harmsen W., Zinsmeister A.R., Cosnes J., et al. Validation of predictors of 5-year disabling CD in a population-based cohort from Olmsted County, Minnesota 1983-1996. Gastroenterology 2007, 132(Suppl 2). S17.
36. Vermeire S., van Assche G., Rutgeerts P. Review article: altering the natural history of Crohn's disease-evidence for and against current therapies. Aliment Pharmacol Ther 2007, 25:3-12.
37. Lémann M., Mary J.Y., Duclos B., Veyrac M., Dupas J.L., Delchier J.C., et al. Infliximab plus azathioprine for steroid dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology 2006, 130:1054-1061.
38. Mantzaris G.J., Ployzou P., Karagiannidis A., Christidou A., Koilakou S., Tsounis D., et al. A prospective, randomized trial of infliximab (IFX) and azathioprine (AZA) for the induction and maintenance of remission of steroid-dependent Crohn's disease. Gastroenterology 2004, 126:A437.
39. Costes L., Colombel J.F., Mary J.Y., Duclos B., Veyrac M., Dupas J.L., et al. Long term follow up of a cohort of steroid-dependent Crohn's disease patients included in a randomized trial evaluating short term infliximab combined with azathioprine. Gastroenterology 2008, 134:A134.
40. Rutgeerts P., Sandborn W.J., Feagan B., Reinisch W., Olson A., Johanns J., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005, 353:2462-2476.
41. Present D.H., Rutgeerts P., Targan S., Hanauer S.B., Mayer L., van Hogezand R.A., et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999, 340:1398-1405.
42. Sands B.E., Anderson F.H., Bernstein C.N., Chey W.Y., Feagan B.G., Fedorak R.N., et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004, 350:876-885.
43. Colombel J.F., Schwartz D.A., Sandborn W.J., Kamm M.A., d'Haens G., Rutgeerts P., et al. Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut 2009, 58:940-948.
44. Hinojosa J., Gomollon F., Garcia S., Bastida G., Cabriada J.L., Saro C., et al. Efficacy and safety of short-term adalimumab treatment in patients with active Crohn's disease who lost response or showed intolerance to infliximab: a prospective, open-label, multicentre trial. Aliment Pharmacol Ther 2007, 25:409-418.
45. Regueiro M., Mardini H. Treatment of perianal fistulizing Crohn's disease with infliximab alone or as an adjunct to exam under anesthesia with seton placement. Inflamm Bowel Dis 2003, 9:98-103.
46. Topstad D.R., Panaccione R., Heine J.A., Johnson D.R., MacLean A.R., Buie W.D., et al. Combined seton placement, infliximab infusion, and maintenance immunosuppressives improve healing rate in fistulising anorectal Crohn's disease. A single center experience. Dis Colon Rectum 2003, 46:577-583.
47. Hyder S.A., Travis S.P.L., Jewell D.P., McC Mortensen N.J., George B.D., et al. Fistulating anal Crohn's disease: results of combined surgical and infliximab treatment. Dis Colon Rectum 2006, 49:1837-1841.
48. Gaertner W.B., Decanini A., Mellgren A., Lowry A.C., Goldberg S.M., Madoff R.D., et al. Does infliximab infusion impact results of operative treatment for Crohn's perianal fistulas?. Dis Colon Rectum 2007, 50:1754-1760.
49. West R.L., van der Woude C.J., Hansen B.E., Felt-Bersma R.J., van Tilburg A.J., Drapers J.A., et al. Clinical and endosonographic effect of ciprofloxacin on the treatment of perianal fistulae in Crohn's disease with infliximab: a double-blind placebo-controlled study. Aliment Pharmacol Ther 2004, 20:1329-1336.
50. Domènech E., Hinojosa J., Nos P., Garcia-Planella E., Cabré E., Bernal I., et al. Clinical evolution of luminal and perianal Crohn's disease after inducing remission with infliximab: how long should patients be treated?. Aliment Pharmacol Ther 2005, 22:1107-1113.
51. van Assche G., Vanbeckevoort D., Bielen D., Coremans G., Aerden I., Noman M., et al. Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn's disease. Am J Gastroenterol 2003, 98:332-339.
52. Bell S.J., Halligan S., Windsor A.C., Williams A.B., Wiesel P., Kamm M.A. Response of fistulating Crohn's disease to infliximab treatment assessed by magnetic resonance imaging. Aliment Pharmacol Ther 2003, 17:387-393.
53. Ng S.C., Plamondon S., Gupta A., Burling D., Swatton A., Vaizey C.J., et al. Prospective evaluation of anti-tumor necrosis factor therapy guided by magnetic resonance imaging for Crohn's perineal fistulas. Am J Gastroenterol 2009, 104:2973-2986.
54. Spradlin N.M., Wise P.E., Herline A.J., Muldoon R.L., Rosen M., Schwartz D.A. A randomized prospective trial of endoscopic ultrasound to guide combination medical and surgical treatment for Crohn's perianal fistulas. Am J Gastroenterol 2008, 103:2527-2535.
55. Poggioli G., Laureti S., Pierangeli F., Rizzello F., Ugolini F., Gionchetti P., et al. Local injection of infliximab for the treatment of perianal Crohn's disease. Dis Colon Rectum 2005, 48:768-774.
56. Asteria C.R., Ficari F., Bagnoli S., Milla M., Tonelli F. Treatment of perianal fistulas in Crohn's disease by local injection of antibody to TNF-alpha accounts for a favourable clinical response in selected cases: a pilot study. Scand J Gastroenterol 2006, 41:1064-1072.
57. Andreani S.M., Dang H.H., Grondona P., Khan A.Z., Edwards D.P. Rectovaginal fistula in Crohn's disease. Dis Colon Rectum 2007, 50:2215-2222.
58. de la Poza G., López-Sanroman A., Taxonera C., Marín-Jimenez I., Gisbert J.P., Bermejo F., et al. Genital fistulas in female Crohn's disease patients: clinical characteristics and response to therapy. J Crohns Colitis 2012, 3:276-280.
59. Miehsler W., Reinisch W., Kazemi-Shirazi L., Dejaco C., Novacek G., Ferenci P., et al. Infliximab: lack of efficacy on perforating complications in Crohn's disease. Inflamm Bowel Dis 2004, 10:36-40.
60. Parsi M.A., Lashner B.A., Achkar J.P., Connor J.T., Brzezinski A. Type of fistula determines response to infliximab in patients with fistulous Crohn's disease. Am J Gastroenterol 2004, 99:445-449.
61. Sorrentino D., Terrosu G., Avellini C., Malero S. Infl{ligature}iximab with low-dose methotrexate for prevention of postsurgical recurrence of ileocolonic Crohn disease. Arch Intern Med 2007, 167:1804-1807.
62. Sorrentino D., Paviotti A., Terrosu G., Avellini C., Geraci M., Zarifi D. Low-dose maintenance therapy with infliximab prevents postsurgical recurrence of Crohn's disease. Clin Gastroenterol Hepatol 2010, 8:591-599.
63. Regueiro M., Schraut W., Baidoo L., Kip K.E., Sepulveda A.R., Pesci M., et al. Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology 2009, 136:441-450.
64. Yoshida K., Fukunaga K., Ikeuchi H., Kamikozuru K., Hida N., Ohda Y., et al. Scheduled infliximab monotherapy to prevent recurrence of Crohn's disease following ileocolic or ileal resection: A 3-year prospective randomized open trial. Inflamm Bowel Dis 2012, 18:1617-1623.
65. De Cruz P., Kamm M., Hamilton A.L., Ritchie K., Gorelik A., Liew D., et al. Adalimumab prevents post-operative Crohn's disease recurrence and is superior to thiopurines: Early results from the prospective POCER study. J Crohns Colitis 2012, 6:S146.
66. Papamichael K., Archavlis E., Lariou C., Mantzaris G.J. Adalimumab for the prevention and/or treatment of post-operative recurrence of Crohn's disease: A prospective, two-year, single center, pilot study. J Crohns Colitis 2012, 6:924-931.
67. Aguas M., Bastida G., Cerrillo E., Beltrán B., Iborra M., Sánchez-Montes C., et al. Adalimumab in prevention of postoperative recurrence of Crohn's disease in high-risk patients. World J Gastroenterol 2012, 18:4391-4398.
68. d'Haens G.R., Vermeire S., van Assche G., Noman M., Aerden I., Van Olmen G., et al. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial. Gastroenterology 2008, 135:1123-1139.
69. Mañosa M., Cabré E., Bernal I., Esteve M., García-Planella E., Ricart E., et al. Azatioprina frente a azatioprina con metronidazol para la prevención de la recurrencia endoscópica posquirúrgica en la enfermedad de Crohn: estudio aleatorizado,doble ciego y controlado con placebo. Gastroenterol Hepatol 2012, 35:148.
70. Lawson M.M., Thomas A.G., Akobeng A.K. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2006, 3:CD005112.
71. Gisbert J.P., González-Lama Y., Maté J. Systematic review:Infliximab therapy in ulcerative colitis. Aliment Pharmacol Ther 2007, 25:19-37.
72. Ferrante M., Vermiere S., Fidder H., Schnitzler F., Noman M., van Assche G., et al. Long-term outcome after infliximab for refractory ulcerative colitis. J Crohns Colitis 2008, 2:219-225.
73. Sandborn W.J., Rutgeerts P., Feagan B., Reinisch W., Olson A., Johanns J., et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology 2009, 137:1250-1260.
74. Reinisch W., Sandborn W.J., Hommes D., d'Haens G., Hanauer S., Schreiber S., et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011, 60:780-787.
75. Reinisch W., Sandborn W.J., Kumar A., Pollack P.F., Lazar A., Thakkar R. 52-week clinical efficacy with adalimumab in patients with moderately to severely active ulcerative colitis who failed corticosteroids and/or immunosuppresants. J Crohns Colitis 2011, 5:S10.
76. Sandborn W.J., van Assche G., Reinisch W., Colombel J.F., d'Haens G., Wolf D.C., et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012, 142:257-265.
77. Gies K., Kroeker I., Wong K., Fedorak N. Treatment of ulcerative colitis with adalimumab or infliximab:long-term follow-up of a single-centre cohort. Aliment Pharmacol Ther 2010, 32:522-528.
78. Ferrante M., Karmiris K., Compernolle G., Ballet V., Vermeire S., Noman M., et al. Efficacy of adalimumab in patients with ulcerative colitis: restoration of serum levels after dose escalation results in a better long-term outcome. Gut 2011, 60:72.
79. Taxonera C., Estellés J., Fernández-Blanco I., Merino O., Marín-Jiménez I., Barreiro-de-Acosta M., et al. Adalimumab induction and maintenanace therapy for patients with ulcerative colitis previously treated with infliximab. Aliment Pharmacol Ther 2011, 33:340-348.
80. García-Bosch O., Gisbert J.P., Cañas-Ventura A., Merino O., Cabriada J.L., García-Sánchez V., et al. Observational study on the efficacy of adalimumab for the treatment of ulcerative colitis and predictors of outcome. J Crohns Colitis 2012,http://dx.doi.org/10.1016/j.crohns.2012.10.004.
81. Järnerot G., Hertervig E., Friis-Liby I., Blomquist L., Karlén P., Grännö C., et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo controlled study. Gastroenterology 2005, 128:1805-1811.
82. Gustavsson A., Järnerot G., Hertervig E., Friis-Libby I., Blomquist L., Karlen P., et al. Clinical trial: colectomy after rescue therapy in ulcerative colitis -3-year follow-up of the Swedish-Danish controlled infliximab study. Aliment Pharmacol Ther 2010, 32:984-989.
83. Laharie D., Bourreille A., Branche J., Allez M., Bouhnik Y., Filippi J., et al. Ciclosporine versus infliximab in acute severe ulcerative colitis refractory to intravenous steroids: a randomized study. Lancet 2012, 380:1909-1911.
84. Maser E.A., Deconda D., Lichtiger S., Ullman T., Present D.H., Kornbluth A. Cyclosporine and infliximab as rescue therapy for each other in patients with steroid-refractory ulcerative colitis. Clin Gastroenterol Hepatol 2008, 6:1112-1116.
85. Mañosa M., Lopez San Román A., Garcia-Planella E., Bastida G., Hinojosa J., Gonzalez-Lama Y., et al. Infliximab rescue therapy after cyclosporin failure in steroid-refractory ulcerative colitis. Digestion 2009, 80:30-35.
86. Leblanc S., Allez M., Seksik P., Flourié B., Peeters H., Dupas J.L., et al. Successive treatment with cyclosporine and infliximab in steroid-refractory ulcerative colitis. Am J Gastroenterol 2011, 106:771-777.
87. Chaparro M., Burgueño P., Iglesias E., Panés J., Muñoz F., Bastida G., et al. Infliximab salvage therapy after failure of ciclosporin in corticosteroid-refractory ulcerative colitis: a multicentre study. Aliment Pharmacol Ther 2012, 35:275-283.
88. Armuzzi A., Pugliese D., Danese S., Rizzo G., Felice C., Mar M., et al. Infliximab in steroid-dependent ulcerative colitis: efficacy and predictors of clinical and endoscopic remission. Gastroenterology 2012, 142:S1-S205.
89. Barreiro-de Acosta M., Lorenzo A., Mera J., Dominguez-Muñoz J.E. Mucosal healing and steroid-sparing associated with infliximab for steroid-dependent ulcerative colitis. J Crohns Colitis 2009, 3:271-276.
90. Barreiro-Acosta M., García-Bosch O., Souto R., Mañosa M., Miranda J., García-Sanchez V., et al. Efficacy of infliximab rescue therapy in patients with chronic refractory pouchitis: a multicenter study. Inflamm Bowel Dis 2012, 18:812-817.
91. Ferrante M., van Assche G., Vermeire S., Noman N., de Hertogh G., Wolthuis A., et al. Patients with refractory pouchitis receiving adalimumab may avoid permanent ileostomy. J Crohns Colitis 2012, 6:S114.
92. Barreiro-de Acosta M., García-Bosch O., Gordillo J., Mañosa M., Menchén L., Souto R., et al. Efficacy of adalimumab rescue therapy in patients with chronic refractory pouchitis previously treated with infliximab: a case series. Eur J Gastroenterol Hepatol 2012, 24:756-758.
93. Braun J., Deodhar A., Dijkmans B., Geusens P., Sieper J., Williamson P., et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period. Arthritis Rheum 2008, 59:1270-1278.
94. van der Heijde D., Schiff M.H., Sieper J., Kivitz A.J., Wong R.L., Kupper H., et al. Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial. Ann Rheum Dis 2009, 68:922-929.
95. Rispo A., Scarpa R., di Girolamo E., Cozzolino A., Lembo G., Atteno M., et al. Infliximab in the treatment of extra-intestinal manifestations of Crohn's disease. Scand J Rheumatol 2005, 34:387-391.
96. Generini S., Giacomelli R., Fedi R., Fulminis A., Pignone A., Frieri G., et al. Infliximab in spondyloarthropathy associated with Crohn's disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations. Ann Rheum Dis 2004, 63:1664-1669.
97. Brooklyn T.N., Dunnill M.G., Shetty A., Bowden J.J., Williams J.D., Griffiths C.E., et al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut 2006, 55:505-509.
98. Regueiro M., Valentine J., Plevy S., Fleisher M.R., Lichtenstein G.R. Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease. Am J Gastroenterol 2003, 98:1821-1826.
99. Cariñanos I., Barreiro de Acosta M., Domènech E. Adalimumab for pyoderma gangrenosum associated with inflammatory bowel disease. Inflamm Bowel Dis 2011, 17:153-154.
100. Suhler E.B., Smith J.R., Giles T.R., Lauer A.K., Wertheim M.S., Kurz D.E., et al. Infliximab therapy for refractory uveitis: 2-year results of a prospective trial. Arch Ophthalmol 2009, 127:819-822.
101. Doctor P., Sultan A., Syed S., Christen W., Bhat P., Foster C.S. Infliximab for the treatment of refractory scleritis. Br J Ophthalmol 2010, 94:579-583.
102. Mahadevan U., Cucchiara S., Hyams J.D., Steinwurz F., Nuti F., Travis S., et al. The London Position Statement of the World Congress of Gastroenterology on biological therapy for IBD with the European Crohn's and Colitis Organization: Pregnancy and Pediatrics. Am J Gastroenterol 2011, 106:214-223.
103. Hyams J., Crandall W., Kugathasan S., Grffiths A., Olson A., Johanns J., et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology 2007, 132:863-873.
104. Hyams J., Damaraju L., Blank M., Johanns J., Guzzo C., Winter H.S., et al. Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitis. Clin Gastroenterol Hepatol 2012, 10:391-399.
105. Hyams J., Griffiths A., Markowitz J., Baldassano R., Faubion W., Colletti R., et al. Safety and efficacy of adalimumab for moderate to severe Crohn's disease in children. Gastroenterology 2012, 143:365-374.
106. Faubion W.A., Loftus E.V., Harmsen W.S., Zinsmeister A.R., Sandborn W.J. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001, 121:255-260.
107. Munkholm P., Langholz E., Davidsen M., Binder V. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 1994, 35:360-362.
108. Ho G.T., Chiam P., Drummond H., Loane J., Arnott I.D., Satsangi J. The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5-year UK inception cohort. Aliment Pharmacol Ther 2006, 24:319-330.
109. Lichtenstein G.R., Feagan B., Cohen R., Salzberg B., Diamond R., Price S., et al. Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT registry. Am J Gastroenterol 2012, 107:1409-1422.
110. Toruner M., Loftus E.V., Harmsen W.S., Zinsmeister A.R., Orenstein R., Sandborn W.J., et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008, 134:929-936.
111. Ferrante M., d'Haens G., Rutgeerts P., Vermeire S., van Assche G. Optimizing biologic therapies for inflammatory bowel disease (ulcerative colitis and Crohn's disease). Curr Gastroenterol Reports 2009, 11:504-508.
112. Allez M., Vermeire S., Mozziconacci N., Michetti P., Laharie D., Louis E., et al. The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn's disease alter failure of two other anti-TNF antibodies. Aliment Pharmacol Ther 2010, 31:92-101.
113. Rutgeerts P., Diamond R.H., Bala M., Olson A., Lichtenstein G.R., Bao W., et al. Scheduled maintenance treatment with Infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc 2006, 63:433-442.
114. Lichtenstein G.R., Yan S., Bala M., Hanauer S. Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. Am J Gastroenterol 2004, 99:91-96.
115. Lichtenstein G.R., Bala M., Han C., DeWoody K., Schaible T. Infliximab improves quality of life in patients with Crohn's disease. Inflamm Bowel Dis 2002, 8:237-243.
116. Rutgeerts P., Feagan B.G., Lichtenstein G.R., Mayer L.F., Schreiber S., Colombel J.F., et al. Comparation of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004, 126:402-413.
117. Hanauer S.B., Wagner C.L., Bala M., Mayer L., Travers S., Diamond R.H., et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004, 2:542-553.
118. Baert F., Noman M., Vermeire S., van Assche G., d'Haens G., Carbonez A., et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003, 348:601-608.
119. Rutgeerts P., d'Haens G., Targan S., Vasiliauskas E., Hanauer S.B., Present D.H., et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999, 117:761-769.
120. Reinisch W., Sandborn W.J., Rutgeerts P., Feagan B.G., Rachmilewitz D., Hanauer S.B., et al. Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies. Inflamm Bowel Dis 2012, 18:201-211.
121. Sandborn W.J., Hanauer S.B., Rutgeerts P., Fedorak R.N., Lukas M., MacIntosh D.G., et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007, 56:1232-1239.
122. Gisbert J., Panés J. Loss of response and requirement of Infliximab dose intensification in Crohn's disease: a review. Am J Gastroenterol 2009, 104:760-767.
123. Billioud V., Sandborn W.J., Peyrin-Biroulet L. Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review. Am J Gastroenterol 2011, 106:674-684.
124. Ordas I., Mould D.R., Feagan B.G., Sandborn W.J. Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. Clin Pharmacol Ther 2012, 91:635-646.
125. Maser E.A., Villela R., Silverberg M.S., Greenberg G.R. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol 2006, 4:1248-1254.
126. Vermeire S., Noman M., van Assche G., Baert F., d'Haens G., Rutgeerts P. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut 2007, 56:1226-1231.
127. Karmiris D., Paintaud G., Noman M., Magdelaine-Beuzelin C., Ferrante M., Degenne D., et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology 2009, 137:1628-1640.
128. Chaparro M., Panés J., García V., Merino O., Nos P., Domènech E., et al. Long-term durability of response to adalimumab in Crohn's disease. Inflamm Bowel Dis 2012, 18:685-690.
129. Katz L., Gisbert J.P., Manoogian B., Lin K., Steenholdt C., Mantzaris G.J., et al. Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response. Inflamm Bowel Dis 2012, 18:2026-2033.
130. Kopylov U., Mantzaris G.J., Katsanos K.H., Reenaers C., Ellul P., Rahier J.F., et al. The efficacy of shortening the dosing interval to once every six weeks in Crohn's patients losing response to maintenance dose of infliximab. Aliment Pharmacol Ther 2011, 33:349-357.
131. Sandborn W.J. Current directions in IBD therapy: what goals are feasible with biological modifiers?. Gastroenterology 2008, 135:1442-1447.
132. Chaparro M., Barreiro-de Acosta M., Garcia-Planella E., Domènech E., Bermejo F., Calvet X., et al. Effectiveness of a dose «de-escalation» strategy with anti-TNF drugs in patients with Crohn's disease (CD). J Crohns Colitis 2011, 5:S103.
133. Sprakes M.B., Hamlin P.J., Warren L., Greer D., Ford A.C. Adalimumab as second line anti-tumour necrosis factor alpha therapy for Crohn's disease: A single centre experience. J Crohns Colitis 2011, 5:324-331.
134. Chaparro M., Andreu M., Barreiro-de Acosta M., García-Planella E., Ricart E., Domènech E., et al. Effectiveness of infliximab after adalimumab failure in Crohn's disease. World J Gastroenterol 2012, 18:5219-5224.
135. Rutgeerts P., Vermeire S., Van Assche G. Predicting the response to infliximab from trough serum levels. Gut 2010, 59:7-8.
136. Ordás I., Feagan B.G., Sandborn W.J. Therapeutic drug monitoring of tumor necrosis factor antagonist in inflammatory bowel disease. Clin Gastroenterol Hepatol 2012, 10:1079-1087.
137. Pariente B., de Chambrun G.P., Hrzysiek R., Desroches M., Louis G., De Cassan C., et al. Trough levels and antibodies to infliximab may not predict response to intensification of infliximab therapy in patients with inflammatory bowel disease. Inflamm Bowel Dis 2012, 18:1199-1206.
138. Louis E., Mary J.Y., Vernier-Massouille G., Grimaud J.C., Bouhnik Y., Laharie D., et al. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 2012, 142:63-70.
139. Domènech E., Zabana Y., Mañosa M., García-Planella E., Cabré E., Gassull M.A. Infliximab reintroduction is not associated to a higher rate of immune-related adverse effects in patients with inflammatory bowel disease initially treated with a three-infusion induction regimen. J Clin Gastroenterol 2010, 44:34-37.
140. Hommes D.W., Oldenburg B., van Bodegraven A.A., van Hogezand R.A., de Jong D.J., Romberg-Camps M.J., et al. Guidelines for treatment with infliximab for Crohn's disease. Neth J Med 2006, 64:219-229.
141. Lichstenstein G.R., Diamond R.H., Wagner C.L., Fasanmade A.A., Olson A.D., Marano C.W., et al. Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials. Aliment Pharmacol Ther 2009, 30:210-226.
142. Colombel J.F., Rutgeerts P., Reinisch W., Mantzaris G.J., Kornbluth A., Rachmilewitz D., et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010, 362:1383-1395. SONIC Study Group.
143. Gomollón F., Gisbert J.P. ¿Es necesario asociar inmunomoduladores al tratamiento biológico en la enfermedad inflamatoria intestinal?. Gastroenterol Hepatol 2010, 33:43-53.
144. Panaccione R., Ghosh S., Middleton S., Velazquez J.R.M., Khalif I., Flint L., et al. Infliximab, azathioprine,or infliximab + azathioprine for treatment of moderate to severe UC SUCCESS trial. J Crohns Colitis 2011, 5:S8.
145. Feagan B., Panaccione R., Enns R.A., Bernstein C.N., Ponich T.R., Bourdages R., et al. A randomized trial of methotrexate in combination with infliximab for the treatment of Crohn's disease. Gastroenterology 2008, 135:294-295.
146. Sokol H., Seksik P., Carrat F., Nion-Larmurier I., Vienne A., Beaugerie L., et al. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy. Gut 2010, 59:1363-1368.
147. Reenaers C., Louis E., Belaiche J., Seidel L., Keshav S., Travis S. Does co-treatment with immunosuppressors improve outcome in patients with Crohn's disease treated with adalimumab?. Aliment Pharmacol Ther 2012, 36:1040-1048.
148. Oussalah A., Chevaux J.B., Fay R., Sandborn W.J., Bigard M.A., Peyrin-Biroulet L. Predictors of infliximab failure after azathioprine withdrawal in Crohn's disease treated with combination therapy. Am J Gastroenterol 2010, 105:1142-1149.
149. Mould D.R., Green B. Pharmacokinetics and pharmacodynamics of monoclonal antibodies: concepts and lessons for drug development. Biodurgs 2010, 24:23-39.
150. Guerra I., Chaparro M., Bermejo F., Gisbert J.P. Utility of measuring serum concentrations of anti-TNF agents and anti-drug antibodies in inflammatory bowel disease. Curr Drug Metab 2011, 12:594-598.
151. Cassinotti A., Travis S. Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: a critical systematic review. Inflamm Bowel Dis 2009, 15:1264-1275.
152. van Assche G., Magdelaine-Beuzelin C., d'Haens G., Baert F., Noman M., Vermeire S., et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 2008, 134:1861-1868.
153. Lichtenstein G.R., Feagan B.G., Cohen R.D., Salzberg B.A., Diamond R.H., Chen D.M., et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006, 4:621-630.
154. Cottone M., Kohn A., Daperno M., Armuzzi A., Guidi L., D'Inca R., et al. Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol 2011, 9:30-35.
155. Loras C., Gisbert J.P., Mínguez M., Merino O., Bujanda L., Saro C., et al. Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy. Gut 2010, 59:1340-1346.
156. Beaugerie L., Brousse N., Bouvier A.M., Colombel J.F., Lémann M., Cosnes J., et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009, 374:1617-1625. CESAME Study Group.
157. Peyrin-Biroulet L., Khosrotehrani K., Carrat F., Bouvier A.M., Chevaux J.B., Simon T., et al. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology 2011, 141:1621-1628. Cesame Study Group.
158. Siegel C.A., Finlayson S., Sands B., Tosteson A. Adverse events do not outweight benefits of combination therapy for Crohn's disease in a decision analytic model. Clin Gastroenterol Hepatol 2012, 10:46-51.
159. Loftus E.V., Johnson S.J., Wang S.T., Wu E., Mulani P.M., Chao J. Risk-benefit analysis of adalimumab versus traditional non-biologic therapies for patients with Crohn's disease. Inflamm Bowel Dis 2011, 17:127-140.
160. Dixon W.G., Abrahamowiccz M., Beauchamp M.E., Ray D.W., Bernatsky S., Suissa S., et al. Inmediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case-control analysis. Ann Rheum Dis 2012, 71:1128-1133.
161. Aubin F., Carbonnel, Wendling D. The complexity of adverse side-effects to biological agents. J Crohns Colitis 2012, 10.1016/j.crohns.2012.06.024.
162. Fallahi-Sichani M., Flynn J.L., Linderman J.J., Kirschner D.E. Differential risk of tuberculosis reactivation among anti-TNF therapies is due to drug binding kinetics and permeability. J Immunol 2012, 188:3169-3178.
163. Singh J.A., Wells G.A., Christensen R., Tanjong E., Maxewll L., MacDonald J.K., et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011, 2:CD008794.
164. Busquets N., Carmona L., Surís X. Revisión sistemática: eficacia y seguridad del tratamiento anti-TNF en pacientes ancianos. Reumatol Clín 2011, 7:104-112.
165. Dixon W., Felson D.T. Is Anti-TNF therapy safer than previously thought?. JAMA 2011, 306:2380-2381.
166. Burmester G.R., Mease P., Dijkmans B.A.C., Gordon K., Lovell D., Panacione R., et al. Adalimumab safety and mortality rates from global trials of six immune-mediated inflammatory diseases. Ann Rheum Dis 2009, 68:1863-1868.
167. Burmester G.R., Panaccione R., Gordon K.B., Mcllraith M.J., Lacerda A.P. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiophatic arthritis, ankylosisng spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Ann Rheum Dis 2012, 10.1136/annrheumdis-2011-201244.
168. Lichtenstein G.R., Rutgeerts P., Sandborn W., Sands B., Diamond R.H., Blank M., et al. A pooled analysis of infections, malignancy and mortality in infliximab-and immunomodulator-treated adult patients with inflammatory bowel disease. Am J Gastroenterol 2012, 107:1051-1063.
169. Viget N., Vernier-Marsouille F.G., Salmon-Ceron D., Yazdanpanah Y., Colombel J.F. Opportunistic infections in patients with inflammatory bowel disease: prevention and diagnosis. Gut 2008, 57:549-558.
170. Ananthakrishnan A.N., McGinley E.L. Infection-related hospitalizations are associated with increased mortality in patients with inflammatory bowel diseases. J Crohns Colitis 2013, 7:107-112.
171. Grijalva C.G., Chen L., Delzell E., Baddley J.W., Beukelman T., Winthrop K.L., et al. Initiation of tumor necrosis factor-alfa antagonists and the risk of hospitalization for infection in patients with autoinmune diseases. JAMA 2011, 306:2331-2339.
172. Beaugerie L. Inflammatory Bowel Disease therapies and cancer risk: where are we and where are we going?. Gut 2012, 61:476-483.
173. Deepak P., Sifuentes H., Sherid M., Stobaugh D., Sadozai Y., Ehrenpreis E.D. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study. Am J Gastroenterol 2013, 108:99-105.
174. Siegel C.A., Marden S.M., Persing S.M., Larson R.J., Sands B.E. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease. A meta-analysis. Clin Gastroenterol Hepatol 2009, 7:874-881.
175. Bewtra M. Lymphoma in inflammatory bowel disease and treatment decisions. Am J Gastroenterol 2012, 107:964-970.
176. Kotlyar D.S., Blonski W., Diamond R.H., Wasik M., Lichtenstein G.R. Hepatosplenic T-cell lymphoma in inflammatory bowel disease: a possible thiopurine-induced chromosomal abnormality. Am J Gastroenterol 2010, 105:2299-2301.
177. Stallman A., Hagel S., Bruns T. Adverse effects of biologics used for treating IBD. Best Pract Res Clin Gastroenterol 2010, 24:167-182.
178. Miehsler W., Novacek G., Wenzl H., Vogelsang H., Knoflach P., Kaser A., et al. Austrian Society of Gastroenterology and Hepatology. A decade of infliximab: the Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease. J Crohns Colitis 2010, 4:221-256.
179. van Assche G. Immunogenicity of anti-TNF antibodies. Has the veil been lifted?. Gut 2011, 60:285-286.
180. Collamer A.N., Battafarano D. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis. Semin Arthritis Rheum 2010, 40:233-240.
181. Guerra I., Algaba A., Pérez-Calle J.L., Chaparro M., Marín-Jiménez I., García-Castellanos R., et al. Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: a report of 21 cases J Crohns Colitis 2012, 6:518-523.
182. Denadai R., Teixeira F.V., Steinwurz F., Romiti R., Saad-Hossne R. Induction or exacerbation of psoriatic lesions during anti-TNF-α therapy for inflammatory bowel disease: a systematic literature review based on 222 cases. J Crohns Colitis 2012, http://dx.doi.org/10.1016/j.crohns.2012.08.007.
183. Cleynen I., Vermeire S. Paradoxical inflammation induced by anti-TNF agents in patients with IBD. Nat Rev Gastroenterol Hepatol 2012, 9:496-503.
184. Ali T., Yun L., Rubin D.T. Risk of post-operative complications associated with anti-TNF therapy in inflammatory bowel disease. World J Gastroenterol 2012, 18:197-204.
185. Casellas F., Robles V., Borruel N., Torrejón A., Castells I., Navarro E., et al. Restoration of quality of life of patients with inflammatory bowel disease alter one year with antiTNFα treatment. J Crohns Colitis 2012, 6:881-886.
186. Bongartz T., Kudva Y. Can treatment of chronic inflammatory diseases reduce the risk of diabetes mellitus?. JAMA 2011, 305:2573-2574.
187. Rahier J.F., Ben-Horin S., Chowers Y., Conlon C., De Munter P., D'Haens G., et al. European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2009, 3:47-91.
188. Gisbert J.P., Villagrasa J.R., Rodríguez-Nogueiras A., Chaparro M. Efficacy of hepatitis B vaccination and revaccination and factors impacting on response in patients with inflammatory bowel disease. Am J Gastroenterol 2012, 107:1460-1466.
189. Zhang J., Xie F., Delzell E., Chen L., Winthrop K.L., Lewis J.D., et al. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA 2012, 308:43-49.
190. Rahier J.F., Moutschen M., van Gompel A., van Rasnst M., Louis E., Segaert S., et al. Vaccinations in patients with immune-mediated inflammatory diseases. Rheumatology 2010, 49:1815-1827.
191. Wasan S.K., Baker S.E., Skolnid P.R., Farraye F.A. A practical guide to vaccinating the inflammatory bowel disease patient. Am J Gastroenterol 2010, 105:1231-1238.
192. Ledingham J., Deighton C. British Society for Rheumatology Standards, Guidelines and Audit Working Group. Update on the British Society for Rheumatology guidelines for prescribing TNF alpha blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001). Rheumatology (Oxford) 2005, 44:157-163.
193. Dixon W.G., Watson K.D., Lunt M., Mercer L.K., Hyrich K.L., Symmons D.P. British Society For Rheumatology Biologics Register Control Centre Consortium; British Society for Rheumatology Biologics Register. Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register. Arthritis Care Res (Hoboken) 2010, 62:755-763.
194. Nathan D.M., Angus P.W., Gibson P.R. Hepatitis B and C virus infections and anti-tumor necrosis factor-alpha therapy: guidelines for clinical approach. J Gastroenterol Hepatol 2006, 21:1366-1371.
195. Calabrese L.H., Zein N., Vassilopoulos D. Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection. Ann Rheum Dis 2004, 63(Suppl 2):S18-S24.
196. Schnitzler F., Fidder H., Ferrante M., Ballet V., Noman M., van Assche G., et al. Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy. Inflamm Bowel Dis 2011, 17:1846-1854.
197. van der Woude J., Kolacek S., Dotan I., Oresland T., Vermeire S., Munkholm P., et al. European evidence-based consensus on reproduction in inflammatory bowel disease. J Crohns Colitis 2012, 4:493-510.
198. Casanova M.J., Chaparro M., Domènech E., Mañosa M., Barreiro-de Acosta M., Bermejo F., et al. Safety of immunomodulators and anti-TNF drugs for the treatment of inflammatory bowel disease during pregnancy. Am J Gastroenterol 2012, 10.1038/ajg.2012.430.
199. Gisbert J.P. Safety of immunomodulators and biologics for the treatment of inflammatory bowel disease during pregnancy and breast-feeding. Inflamm Bowel Dis 2010, 16:881-895.
200. Chaparro M., Gisbert J.P. Transplacental transfer of immunosuppressants and biologics used for the treatment of inflammatory bowel disease. Curr Pharm Biotechnol 2011, 12:765-773.
201. Mahadevan U., Wolf D.C., Dubinsky M., Cortot A., Lee S.D., Siegel C.A., et al. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2012, 10.1016/j.cgh.2012.11.011.
202. Cheent K., Nolan J., Shariq S., Kiho L., Pal A., Arnold J. Case report: fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn's disease. J Crohns Colitis 2010, 4:603-605.
203. Mahadevan U., Martin C.F., Sandler R.S., Kane S.V., Dubinsky M., Lewis J.D., et al. PIANO: a 1000 patient prospective registry of pregnancy outcomes in women with IBD exposed to immunomodulators and biologic therapy. Gastroenterology 2012, 142:S149.
204. Habal F.M., Huang V.W. Review article: a decision-making algorithm for the management of pregnancy in the inflammatory bowel disease patient. Aliment Pharmacol Ther 2012, 35:501-515.
205. Ben-Horin S., Yavzori M., Kopylov U., Picard O., Fudim E., Eliakim R., et al. Detection of infliximab in breast milk of nursing mothers with inflammatory bowel disease. J Crohns Colitis 2011, 5:555-558.
206. Fritzsche J., Pilch A., Mury D., Schaefer C., Weber-Schoendorfer C. Infliximab and adalimumab use during breastfeeding. J Clin Gastroenterol 2012, 46:718-719.
207. Bernick S.J., Kane S. Drug transfer to the fetus and to the breastfeeding infant: what do we know?. Curr Drug Deliv 2012, 9:350-355.
208. Stengel J.Z., Arnold H.L. Is infliximab safe to use while breastfeeding?. World J Gastroenterol 2008, 14:3085-3087.
209. Louis E., Boverie J., Dewit O., Baert F., de Vos M., d'Haens G Treatment of small bowel subocclusive Crohn's disease with infliximab: an open pilot study. Acta Gastroenterol Belg 2007, 70:15-19. Belgian IBD Research Group.
210. Sempere L., García V. Recomendaciones para la vacunación de adultos con enfermedad inflamatoria intestinal. Infecciones, vacunas y enfermedad inflamatoria intestinal.¿Qué necesitamos saber 2010, 19-41. MARGE médica books, Barcelona. E. Ricart, V. García, M. Barreiro (Eds.).
211. Beigel F., Schnitzler F., Paul Laubender R., Pfennig S., Weidinger M., Göke B., et al. Formation of antinuclear and double-strand DNA antibodies and frequency of lupus-like syndrome in anti-TNF-α antibody-treated patients with inflammatory bowel disease. Inflamm Bowel Dis 2011, 17:91-98.
212. Esteve M., Loras C., García-Planella E. Inflammatory bowel disease in travelers: choosing the right vaccines and check-ups. World J Gastroenterol 2011, 17:2708-2714.
213. Gisbert J.P., Chaparro M., Esteve M. Review article: prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2011, 33:619-633.
214. Bermejo F., Algaba A., Chaparro M., Taxonera C., López Sanromán A., Guerra I., et al. How frequent are conversions of tuberculosis (TBC) screening tests among infl{ligature}ammatory bowel disease (IBD) patients under anti-TNF treatment?. J Crohns Colitis 2012, 6:S76.
215. Gisbert J.P., Menchén L., García-Sánchez V., Marín I., Villagrasa J.R., Chaparro M. Comparison of the effectiveness of two protocols for vaccination (standard and double dosage) against hepatitis B virus in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2012, 35:1379-1385.